好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Disparities in Multiple Sclerosis Disability Among Migrants to a Universal Healthcare System
Multiple Sclerosis
P4 - Poster Session 4 (5:00 PM-6:00 PM)
1-011

To describe disparities in multiple sclerosis (MS) disability outcomes in migrants to a universal healthcare context.

Socioeconomic determinants of MS outcomes have gained recognition, with racial and ethnic minorities in user-pays systems experiencing worse disability. However, evidence for disparities in universal healthcare settings is mixed. Sweden has a short migration history and comprehensive universal healthcare. We hypothesise that non-Nordic migrants may experience worse MS outcomes due to socioeconomic factors but not healthcare access.

We conducted a population-level cohort study using the Swedish MS Registry, linked to national administrative registries. We included individuals with onset of relapsing MS at working age between 2001-2015, and residing in Sweden prior to onset. The primary exposure was birthplace, categorised as Nordic, Western (Europe, excluding Nordic countries/North America), and Non-Western (Asia, Africa, South America). Outcomes were clinical and work disability, measured as time to confirmed Expanded Disability Status Score (EDSS) 3 and disability pension use. Covariates included onset age, sex, premorbid socioeconomic status (education, individual and household income), and healthcare quality indicators (onset-to-diagnosis and diagnosis-to-treatment times).

Of 6005 participants, 5482 were Nordic-born, 250 migrated from Western regions, and 273 from Non-Western regions. Non-Western migrants had younger onset age (mean(SD) 34.1(7.5) vs 37.9(9.5)), higher male proportion (39.6% vs 29.7%), and lower median income (USD 8330 vs 20761). Diagnosis and treatment times did not differ significantly. Adjusting for age, sex and calendar year, non-Western migrants had higher hazard for work disability (aHR 1.41, 95%CI 1.03-1.93) compared to Nordic-born people. Both Western and Non-Western migrants had a higher hazard of reaching EDSS 3 (aHR 1.72, 95%CI 1.13-2.64; aHR 1.98, 95%CI 1.30-3.01). Estimates became nonsignificant when adjusted for socioeconomic indices and baseline EDSS.

Adverse disability outcomes in non-Western migrants to Sweden may be driven by socioeconomic but not healthcare disparities.

Authors/Disclosures
Olga Ciccarelli, MD, PhD, FRCP (UCL Institute of Neurology)
PRESENTER
Prof. Ciccarelli has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundebeck. Prof. Ciccarelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Ciccarelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Ciccarelli has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Prof. Ciccarelli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEUROLOGY Journal.
Anna He, MBBS (Centre for Neuroscience, Karolinska Institute) Dr. He has nothing to disclose.
Ali Manouchehrinia, PhD (Karolinska Institutet) Dr. Manouchehrinia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Manouchehrinia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Manouchehrinia has received research support from Karolinska Institutet.
Anna Glaser, PhD Dr. Glaser has nothing to disclose.
Kyla A. McKay, PhD (Karolinska Institutet) Dr. McKay has received research support from Canadian Institutes of Health Research. Dr. McKay has received research support from Swedish Research Council for Health, Working Life, and Welfare. Dr. McKay has received research support from ECTRIMS.
Jan A. Hillert, MD (Karolinska Institute, Neurology R54) Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.